Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006449 · ClinicalTrials.gov registry record · Phase 4
Post-Treatment Effects of Naltrexone
A Phase 4 study of Alcoholism, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 1
- Study location
NCT00006449: Completed Phase 4 study of Alcoholism, sponsored by Indiana University.
NCT00006449 is a Phase 4 study of Alcoholism that has completed, run by Indiana University. The registered enrollment target is 160 participants, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006449, a Phase 4 study of Alcoholism, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The aims of this protocol are to compare 3 and 6 months of naltrexone treatment coupled with two psychotherapies that differ in scope and intensity. The effect of these treatments will be assessed with patients who differ in their psychosocial need and resources at their disposal, and in their level of cravings for alcohol.
Conditions Studied
Interventions
- DRUG naltrexone (Revia)
- BEHAVIORAL broad spectrum treatment
- BEHAVIORAL motivational enhancement therapy
Study Locations (1)
Indiana
- Institute of Psychiatric Research, Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2000-09 |
| Est. Completion | 2006-07 |
| Phase | Phase 4 |
What the finished NCT00006449 record still lists
NCT00006449 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 373-participant average among 65 other Alcoholism trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 3 interventions - of which naltrexone (Revia) is the first listed.
NCT00006449 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00006449 about?
NCT00006449 is a clinical study titled "Post-Treatment Effects of Naltrexone". The aims of this protocol are to compare 3 and 6 months of naltrexone treatment coupled with two psychotherapies that differ in scope and intensity. The effect of these treatments will be assessed with patients who differ in their psychosocial need and resources at their disposal, and in their level...
What is the current status of trial NCT00006449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2000-09. Estimated completion is 2006-07.
What conditions does trial NCT00006449 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT00006449?
The interventions under investigation include: naltrexone (Revia) (DRUG), broad spectrum treatment (BEHAVIORAL), motivational enhancement therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00006449?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006449 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006449's enrollment target sits among peer trials
160 26th of 65 higher than 40 of 65 other Alcoholism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcoholism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
COMPLETED · Phase 4
-
Naltrexone, Craving, and Drinking
COMPLETED · Phase 4
-
Sertraline Pharmacotherapy for Alcoholism Subtypes
COMPLETED · Phase 4
-
Naltrexone for Heavy Drinking in Young Adults
COMPLETED · Phase 4
-
Managing Alcoholism in People Who Do Not Respond to Naltrexone
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia